Please assess the completion status of the following clinical trial:

Trial Title: Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study (103860/064)~* Written informed consent obtained from each subject before each blood sampling visit

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- HBV-1 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg+ mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-2 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg+ mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
- HBV-3 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-4 Group (Type: EXPERIMENTAL): neonates born to HBsAg+ and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)
- HBV-5 Group (Type: EXPERIMENTAL): neonates born to HBsAg- and HBeAg- mothers who received a 5-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12 and again a booster dose at Month 60)
- HBV-6 Group (Type: EXPERIMENTAL): neonates born to HBsAg- and HBeAg- mothers who received a 4-dose vaccination regimen (0, 1 and 2-month schedule with a booster dose at Month 12)

Based on this trial design, predict the completion outcome and termination type (if applicable).